share_log

Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target

Cantor Fitzgerald Reiterates Overweight on Lineage Cell Therapeutics, Maintains $6 Price Target

坎托·菲茨杰拉德重申增持Lineage Cell Therapeutics,维持6美元的目标股价
Benzinga ·  2023/07/25 07:56

Cantor Fitzgerald analyst Kristen Kluska reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Overweight and maintains $6 price target.

Cantor Fitzgerald分析师Kristen Kluska重申Lineage Cell Treateutics(AMEX:LCTX)增持股票,并维持6美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发